Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.

@article{Nicholaou2009RegulatoryTA,
  title={Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.},
  author={Theo Nicholaou and Lisa M Ebert and Ian D Davis and Grant Mcarthur and Heather M. Jackson and Nektaria Dimopoulos and Bee Shin Tan and Eugene Maraskovsky and Lena Miloradovic and Wendie Hopkins and Linda Pan and Ralph R. Venhaus and Eric W. Hoffman and Weisan Chen and Jonathan Simon Cebon},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 6},
  pages={2166-73}
}
PURPOSE NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell-mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma. This study examines the clinical and immunologic efficacy of the same… CONTINUE READING